Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Feb 21, 2021; 27(7): 641-653
Published online Feb 21, 2021. doi: 10.3748/wjg.v27.i7.641
Table 1 Demographic characteristics and clinical features of our patient cohort
All (n = 416)Concordance group (n = 274)Discordance group (n = 142)P value
Age (yr)38.67 ± 10.4738.41 ± 10.6339.18 ± 10.180.467
Male, n305 (73.3)209 (76.3)96 (67.6)0.058
BMI (kg/m2)22.90 ± 2.6422.88 ± 2.4922.94 ± 2.920.833
TBIL (μmoL/L)17.11 ± 21.5617.70 ± 23.3015.98 ± 17.730.402
Albumin (g/L)42.50 ± 5.0242.57 ± 5.0542.37 ± 5.000.706
ALT (IU/L)95.25 ± 52.078.90 ± 99.89126.10 ± 118.46< 0.001
AST (IU/L)58.46± 108.8549.05 ± 55.4476.61 ± 62.80< 0.001
PLT (109/L)187.46 ± 56.53186.36 ± 56.86189.59 ± 56.040.916
HBsAg (Log IU/mL)3.42 ± 0.973.38 ± 1.043.50 ± 0.800.258
HBeAg positive (%)237 (57.0)155 (56.6)82 (57.7)0.818
HBV-DNA (Log IU/mL)4.98 ± 2.184.95 ± 2.165.05 ± 2.230.641
PT (s)12.20 ± 0.9812.17 ± 1.0312.25 ± 0.880.387
AFP (ng/mL)11.37 ± 34.5911.98 ± 36.8010.20 ± 29.950.597
LSM (kPa)9.83 ± 7.709.75 ± 7.219.97 ± 5.140.751
Fibrosis stage1, n< 0.001
F0-1175 (42.1)143 (52.2)32 (22.5)
F2106 (25.5)49 (17.9)57 (40.1)
F367 (16.1)23 (8.4)44 (31.0)
F468 (16.3)59 (21.5)9 (6.3)
Inflammation grade1, n< 0.001
A017 (4.1)15 (5.5)2 (1.4)
A1236 (56.7)187 (68.2)49 (34.5)
A2119 (28.6)49 (17.9)70 (49.3)
A344 (10.6)23 (8.4)21 (14.8)